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BACKGROUND: Patients with lower extremity peripheral artery disease (PAD)
frequently experience claudication, a clinical symptom indicative of reduced walking
capacity. Recommended care consists of exercise rehabilitation combined with optimal
medical treatment and surgery. The effects of a single oral dose of sildenafil, a
phosphodiesterase type-5 inhibitor, on patients with claudication are discussed. The
aim of this study was to test the efficacy of a single 100 mg dose of sildenafil compared
to placebo in terms of maximal walking time (MWT) in patients with claudication.
METHODS: The ARTERIOFIL study is a crossover, double-blind, prospective,
randomized, single-center study conducted at Angers University Hospital in France.
MWT (primary endpoint) was assessed using a treadmill test (10% incline; 3.2 km/h).
Secondary endpoints (pain-free walking time (PFWT), transcutaneous oximetry during
exercise and redox cycle parameters and safety) were also studied.
RESULTS: Fourteen patients were included of whom two were ultimately excluded. In
the 12 remaining patients, the MWT was significantly improved during the sildenafil
period compared with the placebo period (300 s [95% CI 172 s-428 s] vs 402 s [95% CI
274 s-529 s] p < 0.01). Sildenafil had no significant effect on pain-free walking time or
skin tissue oxygenation during exercise. According to redox cycle parameters,
sildenafil significantly reduced blood glucose and pyruvate levels and the 3-
hydroxybutyrate/acetoacetate ratio, while there was no significant effect on lactate, 3-
hydroxybutyrate, acetoacetate and free fatty acid levels. Symptomatic transient
hypotension was observed in two women.
CONCLUSIONS: The ARTERIOFIL study has shown that a single 100 mg oral dose of
sildenafil had a significant effect on increase in MWT but had no significant effects on
PFWT and oxygenation parameters in patients with claudication. A double-blind,
prospective, randomized, multicenter study (VIRTUOSE©) is ongoing to evaluate the
chronic effect of six month-long sildenafil treatment on MWT in PAD patients with
claudication.
CLINICAL TRIAL REGISTRATION: This clinical trial was registered at
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